Verein zur Bekämpfung chronischer Infektionskrankheiten e.V.
- vbciev@gmx.de
- +49 172 846 9445
Verein zur Bekämpfung chronischer Infektionskrankheiten e.V.
ISB has widelly investigated metabolomic microbioma behaviour in the recent years.1 The technology core is Mass spectrometry analysis joined to an innovative metabolite database that makes possible to associate host and bacterial metabolic pathway to the bacteria disequilibrium and to pathogenesis.
It is necessary to enlarge the number of metabolites contained in the database so to increase accuracy and precision in bacterial activity detection so to proceed in increasing accuracy and precision in the detection of the activity of pathogen that could be strongly related with different pathogenesis caused by cronical bacteria diseases. These informations not only will make possible to better dect them but also to apply more effective therapies. Two project steps will be required to acheve this goal:
– Biobliographic research to select the metabolite candidates;
– Implementation of the bioinformatic system to improve the bacteria detection;
– In vitro experimental test to check the improved technology;
– In vivo experimental test to check the improved technology with healthy volonteers and control subjects. This step will be done in collaboration with different research institutes (e.g. IRCCS, University).
The needed cost are following summarized
– Bibliographic research to select the metabolite candidates: 5000 €;
– Implementation of the bioinformatic system to improve the bacteria detection 5000 €;
– In vitro experimental test to check the improved technology 5000 €;
– In vivo experimental test to check the improved technology with healthy volonteers and control subjects. This step will be done i collaboration with different research institutes (e.g. IRCCS, University): 15.000 €.
The total amount to be financed is so: 30.000 €
1. Cristoni S, Rossi Bernardi L, Larini M, Natale G, Didomenico N, Varelli M, Conti M, Dorna I, Puccio G. Predicting and preventing intestinal dysbiosis on the basis of pharmacological gut microbiota metabolism. Rapid Commun Mass Spectrom. 2019 Jul 30;33(14):1221-1225. doi: 10.1002/rcm.8461.